Skip to main content

Table 2 Content of fatty acids in granulocytes presented as means with 95% confidence intervals at baseline and after 24 weeks of supplementation for both groups

From: The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial

 

n-3 PUFA  (n = 68)

  

Control  (n = 65)

   
 

Baseline

Week 24

Difference (CI)

Baseline

Week 24

Difference (CI)

P

Palmitic acid (16:0) wt.%

12.32

12.40

0.08 (−0.04 - 0.21)

12.38

12.37

−0.00 (−0.12 - 0.12)

0.33

Stearic acid (18:0) wt %

17.36

17.35

−0.01 (−0.12 - 0.11)

17.41

17.30

−0.11 (−0.24 - 0.01)

0.20

Oleic acid (18:1n-9) wt.%

32.90

33.21

0.30 (0.03; 0.57)

32.97

33.44

0.47 (0.24; 0.70)

0.35

Linoleic acid (18:2n-6) wt. %

9.12

8.62

−0.50 (−0.80; −0.21)

9.32

9.21

−0.11 (−0.26; 0.05)

0.02

AA (20:4n-6) wt %

13.05

11.44

−1.61 (−1.84; −1.38)

13.01

12.80

−0.20 (−0.37; −0.04)

<0.01

Total n-6 wt %

22.17

20.05

−2.12 (−2.47 - -1.76)

22.32

22.01

−0.31 (−0.51 - -0.11)

<0.01

EPA wt %

0.60

1.99

1.40 (1.24; 1.56)

0.53

0.50

−0.03 (−0.08; 0.02)

<0.01

DPA wt %

1.58

2.61

1.03 (0.86; 1.21)

1.46

1.42

−0.04 (−0.10; 0.02)

<0.01

DHA wt %

1.21

2.10

0.89 (0.77; 1.00)

1.14

1.11

−0.02 (−0.07; 0.02)

<0.01

Total n-3 PUFA (DHA + EPA + DPA) wt %

3.39

6.71

3.32 (2.92; 3.71)

3.13

3.03

−0.10 (−0.22; 0.03)

<0.01

  1. AA arachidonic acid, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, DPA docosapentaenoic acid, wt. % weight percent, P P for the difference between the two groups of supplement